Putting Patients First Blog

JUNE 26, 2025

Inclusion of Part B Drugs: Scope, Challenges, and Opportunities The addition of provider-administered therapies covered under Medicare Part B to the IPAY 2028 cycle introduces a fundamentally different reimbursement and care delivery context than that of pharmacy-dispensed Part D drugs.

Drug Pricing

pharmaphorum

APRIL 20, 2021

According to Novartis, Kesimpta is the first targeted B cell therapy for RMS that can be self-administered at home once a month using an autoinjector, avoiding the need for patients to travel to hospital during the pandemic, and easing the pressure on clinicians. billion by 2028. billion in sales in 2028.

Hospitals

pharmaphorum

SEPTEMBER 13, 2022

During his time working in the pathology museum at Guy’s Hospital in London, Hodgkin studied several preserved specimens of human organs affected by disease. The first well-documented case of multiple myeloma was reported in 1844 by renowned British surgeon Samuel Solly. 1844 – First reported case of multiple myeloma.

Chemotherapy

Putting Patients First Blog

FEBRUARY 11, 2025

CMS should also work directly with providers to minimize administrative burdens caused by risk adjustment changes, as increased documentation requirements could further strain providers, particularly those treating high-cost populations. Equally critical is clear and accessible communication with beneficiaries. 3 American Medical Association.

Insurance Coverage and Processing